Data capture is no longer the bottleneck, and whether the lag between a signal and a decision shrinks depends on signal design, AI governance, and vendor orchestration.
|Webcasts|September 26, 2019
Successful Early Phase Drug Development of mAb Drugs
Author(s)SGS
This webcast will provide insights into the better understanding of operational challenges in resourcing and executing seasonal infectious diseases studies. Live: Europe: Thursday, Jun. 27, 2019 at 3pm BST | 4pm CEST On demand available after airing until Jun. 27, 2020. Register free
Register free:
Event Overview:
Several monoclonal antibody (mAb) drugs have been approved or are in the late stage of clinical development within various therapeutic indications. The number of mAbs making it to market will continue to increase thanks to their characteristics.
mAbs have complex pharmacokinetic (PK) and pharmacodynamic (PD) properties compared to small chemical molecules. Analysis of a new compound’s PK and PD properties is an essential step in the early phases of all drug development; but this process is still more complicated for mAbs. Challenging steps in designing FIH trials with mAb drugs remain and include the selection of a safe and appropriate starting dose; the choice of dose escalation steps to achieve the goal of a FIH study; the planning of sufficient and correct follow-up procedures; and the necessary safety monitoring, which considers both the short-term infusion related reactions and delayed PD effects.
In addition, due to safety incidents in the past, authorities look more rigorously towards mAbs, considering many of them to be high-risk medicinal products. A sound early clinical development plan, including appropriate justifications, might help regulatory bodies with their evaluation of what they view as high-risk.
Key Learning Objectives:
- Pharmacological specificities of mAb drugs to consider when starting clinical development
- Starting dose and dose escalation steps in FIH study with mAb drugs
- Study conduct and safety monitoring particularities during FIH trial with mAb drugs
- Regulatory strategies and approaches for smooth mAb development
- Tips & tricks for successful agency interactions in early development
Time and date: Europe: Thursday, Sept. 26, 2019 at 3pm BST | 4pm CEST
North America: Thursday, Oct. 3, 2019 at 11am EDT | 10am CDT | 8am PDT
On demand available after airing until Sept. 26, 2020.
Sponsor: SGS
Register free:
Related to this article
In this Q&A, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, discusses what changes when AI is embedded across protocol strategy, data infrastructure, and workflow tools at once, where governance frameworks tend to fall short, and why CROs must orchestrate AI ecosystems rather than simply aggregate them.
In today’s ACT Brief, we examine what policy changes would help community and rural institutions join research, how Walmart is expanding clinical trial centers into three more states, and how FDA approved Ilumya for adults with active psoriatic arthritis.
The planned sites in Livonia, Las Vegas, and San Antonio would expand a partnership that places clinical research and health screenings inside Walmart stores.
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.
In today’s ACT Brief, we examine why community and rural patients lack access to research as a care option, what makes AI assistants trustworthy in regulated trials, and how FDA draft guidance could let gene editing therapies cover patient-specific variants.
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.
In this video interview, Kent Thoelke, CEO of Paradigm Health, explains why patients in community and rural settings too often lack access to clinical research as a care option, and how closing that gap could improve outcomes and lower long-term costs.
Trending on Applied Clinical Trials Online
1
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
2
What Needs to Happen Beyond the Clinical Trial Modernization Act
3
From Signal to Action: Why Faster Trial Data Isn’t Producing Faster Decisions
4
Walmart and Care Access Plan Three More Clinical Trial Centers in Michigan, Nevada, and Texas
5